The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2020

Filed:

Dec. 19, 2017
Applicant:

Oncomed Pharmaceuticals, Inc., Redwood City, CA (US);

Inventors:

Austin L. Gurney, San Francisco, CA (US);

Aaron Ken Sato, Burlingame, CA (US);

Christopher John Bond, San Mateo, CA (US);

Assignee:

OncoMed Pharmaceuticals, Inc., Redwood City, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61K 45/06 (2006.01); A61K 31/4745 (2006.01); A61K 31/7068 (2006.01); A61K 39/00 (2006.01); A61K 45/00 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61K 31/4745 (2013.01); A61K 31/7068 (2013.01); A61K 39/00 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/00 (2013.01); A61K 45/06 (2013.01); C07K 16/18 (2013.01); C07K 16/22 (2013.01); C07K 16/30 (2013.01); C07K 16/303 (2013.01); C07K 16/3046 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.


Find Patent Forward Citations

Loading…